Last reviewed · How we verify
NCT05773248
ERAS in Colorectal Surgery: Benefits of Late Adoption
trial testing ERAS protocol in Colorectal Cancer in 456 participants. Completed in 30 April 2023.
31 March 2023
Quick facts
| Lead sponsor | University Hospital, Basel, Switzerland |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 456 |
| Start date | 13 March 2023 |
| Primary completion | 31 March 2023 |
| Estimated completion | 30 April 2023 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- ERAS protocol
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
- Colorectal Disorders — all drugs for Colorectal Disorders →
Sponsor
University Hospital, Basel, Switzerland
Who can join
Adults 18 to 99, any sex, with Colorectal Cancer or Colorectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this single-center retrospective cohort study is to explore the effect of late adaptation of an ERAS protocol in a high-volume colorectal surgical unit. The primary endpoint is the surgical outcome measured by early postoperative complications, defined by the comprehensive complications index. Secondary endpoints include amongst others LOS (length of stay), cost analysis, short-term follow-up in the ERAS group.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Enhanced recovery after surgery (ERAS) in colorectal surgery: implementation is still beneficial despite modern surgical and anesthetic care.
Süsstrunk J, Mijnssen R, von Strauss M, Müller BP, et al · · 2023 · cited 11× · PMID 38091109 · DOI 10.1007/s00423-023-03195-7
Verify or expand the search:
- PubMed search for NCT05773248
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ERAS protocol
Trials testing the same drug.
- NCT06984952 — Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy · NA · recruiting
- NCT07087366 — Enhanced Recovery After Surgery(ERAS) Following Gynaecological Oncology Surgery in a Tertiary Level Hospital · NA · recruiting
- NCT07232394 — Early Feeding and Mobilization in Thoracic Surgery · NA · completed
- NCT06729736 — Implementation of the ERAS in Colorectal Cancer Patients: a Single Arm Study · NA · enrolling by invitation
- NCT06489288 — ERAS in Totally Laparoscopic Total Gastrectomy for Gastric Cancer · NA · active not recruiting
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other University Hospital, Basel, Switzerland trials
Trials by the same sponsor.
- NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
- NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
- NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
- NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
- NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05773248 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
- Last refreshed: 28 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05773248.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing